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recurrences for breastRadiation therapy significantly reduces by at least 70% the relative risk of local and regional
cancer after surgery. A positive influence on overall survival has beenclearly demonstrated, especially for patients with a high absolute risk for locoregional
recurrences. However, this is partially counterbalanced by late toxicity (dependent upon
the radiation dose) especially to cardiac structures. Apart from this toxicity, a clear influ-
ence of radiation-therapy-related factors on functional and cosmetic outcome has also
been demonstrated. Over time, technical improvements have led to a marked reduction
in dose to the neighbouring organs, with a consequent drop in acute and late toxicity. This
has also allowed the introduction of shorter radiation schedules, lowering the burden of
treatment to the patient and the hospital. Several tools, techniques and guidelines have
been developed to optimise the balance between the desired reduction in recurrence rates
and side effects.
The multidisciplinary team should discuss all available treatment options for every individ-
ual breast cancer patient. Individualisation of the selection of the optimal combination of
treatments, depending on patient and tumour-related factors, is of utmost importance.
Apart from direct tumour-related outcomes, cosmesis and potential side effects have to
be taken into account. Counselling should include known risk factors for survival and com-
plications, including comorbidity.
Copyright  2013 ECCO - the European CanCer Organisation. All rights reserved.1. Introduction
Radiation therapy (RT) forms an integral component of the
managementofearly-stagebreast cancer.Over theyears, signif-
icant progress – accelerating over time – has resulted from our
growing knowledge of the biology and the natural behaviour of
breast cancer as well as from technical improvements in RT.
While initially research focused on optimising locoregional
disease control by combining surgery with RT, the introduction
of breast-conserving therapy (BCT) initiateda periodof research
aimed at lowering the burden of treatment [1,2]. At the
same time, adjuvant systemic treatment became widely used,
resulting in a reduced risk ofmetastases and thereby improving
overall survival. The interaction between the benefits fromboth
locoregional andsystemic treatmentsopenedtheway to furtherimproving the clinical outcome for breast cancer patients in
terms of survival aswell as quality of life.
The 21st century started with a number of developments,
including fine-tuning of the indications for RT for each indi-
vidual target volume (intact breast, post-mastectomy chest
wall, axillary, internal mammary and supraclavicular lymph
nodes) depending on the clinicopathological features of an
individual patient’s disease, as well as hypofractionation
and accelerated partial breast irradiation.
2. Prognostic factors influencing locoregional
treatment
Several prognostic factors determine the risk of recurrence at
local, regional and distant sites. On the basis of this, recom-
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tients with breast cancer are defined.
Factors influencing the risk of recurrence include tumour
size, tumour grade, margin status, lymph-node involvement,
oestrogen and progesterone receptor status, HER-2/neu status
and patient age. Whereas the relative benefit of locoregional
and systemic therapy remains largely independent of these
factors, they greatly determine the absolute benefit that can
be expected. For systemic therapy they also determine the
selection of its type (endocrine therapy, chemotherapy, trast-
uzumab, or a combination of these).
Age may also influence treatment recommendations as it
helps to predict the relative risk for death related to cancer
compared to death from other causes. In general, treatment
tolerability, especially for chemotherapy, tends to decrease
with increasing age.
Patients who are BRCA1 or BRCA2mutation carriers should
receive extensive counselling to discuss the possible ap-
proaches, including BCT and mastectomy, and even including
prophylactic contralateral mastectomy given their increased
risk of developing a second primary breast cancer in either
breast in the future [3,4].
3. Breast conserving therapy
3.1. Lumpectomy with or without radiation therapy
It is well recognised that up to 80% of patients with invasive
breast cancer may benefit from BCT, which offers rates of dis-
ease control and survival similar to those of mastectomy. This
was confirmed by the meta-analyses of the Early Breast
Cancer Trialists’ Collaborative Group (EBCTCG) [5]. Candidates
for BCT include patients with unicentric disease that can be
removed with negative margins and with acceptable cosmetic
results.
The size of an invasive breast cancer, in relation to overall
breast size, in a patient considering BCT will determine
whether neoadjuvant chemotherapy or endocrine therapy is
required to reduce the size of the primary tumour prior to
definitive surgery. Patients with multicentric tumours and
inflammatory breast cancer are not considered candidates
for BCT. Patientswithmultifocal tumourswithin a single quad-
rant of the breast –which can be removed in a single segmental
resectionwith clearmargins and a cosmetically acceptable re-
sult – may be considered candidates for segmental resection
followed by whole-breast RT. Oncoplastic surgical techniques
that are becoming more widely used clearly extend the range
of possibilities for BCTwith acceptable cosmetic outcomes in
patients that were offered mastectomy in the past.
Excision alone without RT may occasionally be considered
for patients at low risk of recurrence. In these cases, it is rec-
ommended that the negative margins be wide (P10 mm). For
instance, patients older than 70 years with oestrogen-recep-
tor-positive T1 primary tumours may choose to forgo whole
breast RT, if they accept receiving 5 years of endocrine ther-
apy, because of their lower risk of local recurrence in the
breast. However, whole breast irradiation in this setting does
reduce the risk of local recurrence by at least two thirds [6].
Moreover, adjuvant hormonal treatment – which also carries
side effects – can be avoided if RT is given.3.2. Boost
The purpose of the boost is to deliver additional radiation to
the area at the highest risk of harbouring microscopic resid-
ual disease: namely, the primary tumour bed and immedi-
ately surrounding breast parenchyma. Multiple studies have
shown that this area has the highest risk of recurrence in
the breast [7,8].
While the EORTC trial 10801 comparing mastectomy and
BCT demonstrated equivalent overall survival rates for up to
20 years after treatment, a significant difference in local con-
trol was seen between the participating centres, and the high
boost dose of 25 Gy that was used resulted in a significant
proportion of the patients with severe fibrosis and a poor cos-
metic outcome [9]. The next EORTC ‘‘boost’’ trial 22881/10882
paid special attention to quality assurance, fibrosis and cos-
metic scoring. The boost dose was lowered from 25 Gy to
16 Gy, which was randomised against no boost at all. This
trial and two other prospective randomised trials showed that
delivering a boost dose to the tumour bed after whole breast
irradiation significantly reduces the local recurrence rate
[7,10,11]. Young age appears to be the most significant inde-
pendent patient factor related to local recurrence. The abso-
lute effect of the boost – reducing the local recurrence rate
relatively by 41% overall – was much more marked for youn-
ger patients (Fig. 1) [7,12]. The cosmetic results were scored as
excellent to good in 86% of patients receiving no boost and in
71% of patients receiving a boost. Apart from the boost dose,
other predictors for cosmetic outcome included whole breast
dose and megavolt energy, type of boost, energy of electrons,
and use of adjuvant chemotherapy or hormonal therapy [13].
An inhomogeneous dose distribution of whole breast RT neg-
atively influenced the risk for developing fibrosis, similar to
the findings of Donovan and colleagues [14]. Based on this
trial, nomograms have been developed to predict in individual
patients the impact of a boost dose of 16 Gy on the rate of ipsi-
lateral breast relapse (http://research.nki.nl/ibr) and fibrosis
[13,15].
To evaluate the need for a further increase in the boost
dose from 16 Gy to 26 Gy for patients up to 50 years of age,
the ‘‘Young Boost Trial’’ (NCT00212121) was run in The
Netherlands, Germany and France between 2004 and 2011.
Early analysis of the results, without splitting up for the ran-
domisation arm, shows that the estimated local recurrence
rate remains far below the results obtained in trials, despite
the much younger age in the population investigated.3.3. Accelerated partial breast irradiation
As previously mentioned, after lumpectomy with surgical ax-
illary staging, the standard of care is whole breast irradiation
with or without a boost dose. However, accelerated partial
breast irradiation (APBI) is rapidly emerging as a treatment
option for early-stage invasive breast cancer in certain clinical
scenarios. It may be considered in women who areP50 years
of age, with tumours that are pathologically 3 cm or smaller,
and node-negative. Ideally, these patients should be treated
in the framework of clinical trials because of the more limited
long-term data for APBI comparedwith those for whole breast
Fig. 1 – Cumulative incidence of breast cancer recurrence according to age group. Reproduced with permission from [7].
Fig. 2 – Local breast recurrence rate in three consecutive
trials. Reproduced with permission from [19].
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 2 7 –3 6 29irradiation [16–18]. It is expected that in the near future, after
completion of the prospective randomised clinical trials com-
paring APBI with standard whole breast irradiation, a precise
definition of the place of APBI will become available.
3.4. Young patients
It is important to see the clear decrease in local recurrence
rates over time in the EORTC 10801, EORTC 22881–10882 and
Young Boost trials (Fig. 2) [19]. The explanation of this contin-
uous improvement is multifactorial and includes technical
and diagnostic factors and the increasing use of adjuvant sys-
temic treatment. It is well established that chemotherapy and
hormonal treatment reduce local recurrence rates by about
35–50%. Indeed, according to the consensus at the time, virtu-
ally no patient who participated in the EORTC 10801 trial, and
only 31% of the patients participating in the EORTC 22881–
10882 trial, received adjuvant systemic treatment, while in
the Young Boost trial nearly all patients received systemic
treatment, often combined chemotherapy and hormonal
treatment [12]. Therefore, results from the past after BCT in
young patients should not be considered as a contraindica-
tion for offering this treatment today to patients <50 years
of age. Some caution might remain for very young patients
(635 years of age) in view of the relative scarcity of data and
the possibly different aetiological factors in these patients. In-
deed, in two large Dutch population-based cohort studies ofyoung breast cancer patients, conflicting results were found
on comparing BCTwith mastectomy [20,21].
3.5. Ductal carcinoma in situ
For non-invasive disease (ductal carcinoma in situ, DCIS),
treatment options depend on the extent of the disease. For
mammographically detected unifocal lesions, which can be
removed in a single lumpectomy specimen with good cos-
metic results, BCT is an excellent option. Clear surgical mar-
gins of at least 2 mm are recommended [22]. Postoperative
radiation therapy is indicated to eliminate potential residual
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the standard of care after lumpectomy, as it reduces the risk
of recurrence in the breast by approximately 50–60% at
10 years of follow-up [23]. Half of the recurrences are invasive
cancer and half are DCIS, with a similar risk reduction for
both after radiation therapy. A boost dose to the primary tu-
mour bed might further reduce the local recurrence rate
[24]. Axillary surgical lymph node evaluation is not required
for patients with pure DCIS because it is associated with an
extremely low risk of nodal involvement. Sentinel-node
biopsy may be considered in the presence of extensive or
high-grade DCIS, especially if a mastectomy is performed.
For patients with more extensive DCIS, or for those wishing
to avoid radiation therapy, total mastectomy with or without
breast reconstruction is the preferred option.
4. Mastectomy
4.1. Chest wall irradiation
If mastectomy with surgical axillary staging is selected as the
primary surgical treatment option, recommendations for
post-mastectomy radiation therapy (PMRT) are based on the
risk of locoregional failure in the chest wall or in the undis-
sected regional lymphatics (upper part of the axilla including
the infraclavicular region, supraclavicular region, and inter-
nal mammary region). Available data are essentially based
on comprehensive locoregional treatment, making it cur-
rently impossible to define clear recommendations for chest
wall irradiation only.
If the primary tumour is <5 cm in diameter and if there is
no axillary nodal involvement, the risk of locoregional failure
is <10% without PMRT, so RT is not recommended in this clin-
ical scenario [25]. Clinicopathological factors associated with
a high risk (>20%) of locoregional recurrencewithout PMRT in-
clude four or more involved lymph nodes,P20% involvement
of the number of axillary lymph nodes, T4 tumours, and T3
tumours combined with axillary nodal involvement [25,26].
One to three positive lymph nodes after primary chemother-
apy are also associated with a higher risk of locoregional
recurrence. Therefore, PMRT is recommended in all these
clinical settings [27]. If mastectomy with surgical axillary
staging is performed prior to chemotherapy, the current Na-
tional Cancer Comprehensive Network guidelines strongly
suggest that post-chemotherapy radiation be considered to
the chest wall and undissected regional lymphatics, also in
the setting of one to three positive lymph nodes. Other tu-
mour- and patient-related factors that are associated with a
higher risk of locoregional recurrence without PMRT include:
T3, tumour size of P4 cm with involved lymph nodes, age
<40 with involved lymph nodes, grade 3, lobular histology,
lymphovascular invasion and involved lymph nodes, largest
axillary node P2 cm, gross extranodal extension of P2 mm,
involved lymph nodes with fewer than ten axillary lymph
nodes dissected, and premenopausal status with lymphovas-
cular space invasion [28,29]. As the debate on the use of PMRT
in intermediate-risk patient groups continues, most guide-
lines refer to a combination of risk factors [30,31].
Nowadays, most patients presenting with risk factors will
receive adjuvant systemic treatment. Especially in locore-gionally advanced disease (the typical indication for mastec-
tomy), primary systemic treatment is becoming
progressively more popular. In general, the indications for
PMRT remain the same, although the pathological stage is
not reliably known and the response to systemic treatment
might be used for adjusting the recurrence risks. In general,
patients presenting with clinical stage III disease (4 or more
suspicious or confirmed positive lymph nodes on pretreat-
ment ultrasound, cT3N1 disease, or cT4 disease) prior to che-
motherapy should undergo PMRT. Patients presenting with
clinical stage IV disease who experience a complete response
to systemic therapy or those being treated with curative in-
tent should be considered for PMRT as well. In patients with
close or positive margins and clinical T3, N0 disease, PMRT
to at least the chest wall should be considered. PMRT should
also be considered in patients presenting with T1–2, N1
disease and one or more of the following clinicopathological
features: residual tumour size >2 cm, residual lymph-node-
positive disease after chemotherapy, age <40 years and
lymphovascular invasion.
4.2. Radiation therapy and breast reconstruction
The number of women requesting breast reconstruction after
mastectomy is increasing. In particular, immediate breast
reconstruction (IBR) is becoming more popular for breast can-
cer patients who are not good candidates for breast-conserving
therapy. Uncertainty exists about the preferred type (using
implanted material, autologous tissue, or a combination) of
IBR in patients requiring PMRT to minimise the complication
and reoperation rates and to optimise cosmetic outcome.
Other concerns are the safety and efficacy of IBR, the possible
risk of a delay in starting adjuvant systemic treatment and
the influence on the quality of RT delivery in terms of dose
homogeneity and target volume coverage [32,33].
In general, PMRT is associated with a higher rate of capsu-
lar contracture following IBR using an implant. However, good
results can be obtained in the majority of these patients [34].
Fewer data exist on PMRT following IBR using autologous tis-
sue, although most authors report that the outcome in terms
of complication rates and cosmetic results is better when
compared with implant reconstruction only [32,35,36]. Surgi-
cal intervention, including free fat grafting, can be used to im-
prove – if needed – long-term results after IBR and PMRT. Most
data confirm that IBR is not associated with a significant delay
in starting adjuvant therapy. A homogeneous dose of radia-
tion to the chest wall with/without the regional lymph nodes
can be delivered with acceptable heart and lung doses if opti-
mised modern RT techniques – including procedures for
adjustment of respiratory movement, highly conformal 3D
and IMRT – are appropriately used (Fig. 3) [37,38].
Few data are available on the influence of pre-reconstruc-
tion PMRT on tissue expander breast reconstruction. In
general, a higher frequency of capsular contracture and a
slightly higher reoperation rate for procedures using implants
are seen, leading to worse patients’ and surgeons’ subjective
evaluations. On the other hand, a history of PMRT alone
should not dictate the type of reconstruction [39]. Patients
who develop neither severe skin changes nor subcutaneous
fibrosis may still be considered for implant-based breast
Fig. 3 – Individualised treatment plan using multiple electron beams for chest wall irradiation in a patient with an immediate
breast reconstruction with an implant (a) axial slice; (b) sagittal slice).
Table 1 – Risk categories for locoregional relapses after
mastectomy and axillary clearance. Ax LN +, involved
axillary lymph nodes. Reproduced with permission from
[47].
Risk category Low Intermediate High
Tumor stage T1-2 T1-2 T3-4
Number of Ax LN + 0 1-3 > 3
Grade 1-2 3
Vascular invasion - +
Histology ductal lobular
Risk < 10% 10-20% > 20%
Table 2 – Indication for irradiation of the different target
volumes after mastectomy and axillary clearance as well as
for regional radiation therapy (RT) in the framework of
breast-conserving therapy (BCT). Yes, evidence and gener-
ally accepted; Yes?, evidence but not generally accepted;
No?, limited evidence, however advocated by some authors;
No, no evidence. Reproduced with permission from [47].
Risk category Low Intermediate High
Thoracic wall No? Yes? Yes
Supraclavicular No? Yes? Yes
Internal mammary No Yes? Yes?
Axilla No No No
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 2 7 –3 6 31reconstruction [35,40–42]. Pre-reconstruction RT seems not to
influence the overall success rate of reconstruction using
autologous tissue, nor to contribute to postoperative compli-
cations. However, it increases the rate of vascular complica-
tions in free flap breast reconstructions, seen mostly during
surgery itself. In general, the cosmetic outcome and satisfac-
tion in women reconstructed with autologous tissue is higher
than in those with implant-based reconstruction. The opti-
mal timing for breast reconstruction after PMRT is unclear.
Often, an interval of 12 months between PMRT and recon-
struction is advised, but some state that breast reconstruction
with autologous tissue can potentially be performed earlier
[43,44].
5. Regional radiation therapy
The indications for regional RT are independent of the type of
surgery to the breast (BCTor mastectomy). Therefore, most of
what was stated in the subsection ‘‘chest wall irradiation’’ is
also applicable to this chapter.
The EBCTCG overview confirmed that PMRT and RT in the
framework of BCT improves specific and overall survival in all
breast cancer patient subgroups with involved axillary lymph
nodes as well as in node-negative patients treated with BCT
[45]. In most older trials, comprehensive locoregional RTwas
used. Based on this, a division into three risk categories for
locoregional relapse is made with a proposal for selecting
the target volumes for RT (Tables 1 and 2) [46].
The clinically most relevant drainage of the breast tissue is
to the ipsilateral lower axilla. Therefore, staging most often
includes at least a sentinel-node biopsy to estimate the de-
gree of axillary lymphatic involvement by the tumour; this
provides the most important single prognostic factor for pa-
tients with breast carcinoma. In general, nodal involvement
occurs in an orderly fashion [47]. The other major route of
lymphatic spread is via the ipsilateral internal mammary
chain (IMC). They are primarily found in the first three
intercostal spaces. Internal mammary chain drainage is cor-
related with tumour location in the breast [48]. The identifica-
tion rate for IMC disease with sentinel node procedures
depends on the technique of the procedure itself, being high-est with an intra-tumoural injection of tracer followed by a
peri-tumoural injection, and lowest with a subdermal or
peri-areolar injection [49].
Supraclavicular nodal involvement generally represents
stages of advanced regional disease and carries a poorer prog-
nosis. The major route of cancer spread to the supraclavicular
lymph nodes is via the axillary lymph nodes [50].
Since the publication of the ACOSOG Z0011 trial – showing
that axillary surgery is probably not required for patients with
a positive sentinel-node biopsy and treated with BCT, includ-
ing tangential field irradiation to the whole breast – uncer-
tainty exists about RT to a positive axilla without further
axillary clearance [51]. A proposal based on the combination
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developed in the Netherlands.6. Radiation related toxicity
There is ample evidence to suggest that cardiac irradiation is
detrimental, although cardiac consequences of RT of the
breast have long latencies estimated to become detectable
onlyP15 years after treatment. The EBCTCG overview of ran-
domised trials demonstrated that the gain in locoregional
control was not fully translated into an improvement in over-
all survival, suggesting that survival benefit with RT becomes
at least partially offset by increased cardiovascular deaths [5].
In particular, radiation techniques that have incorporated
large volumes of the heart have been shown to negatively im-
pact on overall survival [52].
Therefore,minimising cardiac irradiation is a critical aspect
of treatment planning. Depending on the individual case,
changing the gantry angle, the collimator angle, or shaping –
with small cardiac blocks or MLC leaves – the borders of the
medial and/or lateral tangential fields can result in adequate
coverage of the primary tumour site and most of the breast
while excluding the heart from the high-dose region. These
treatment fieldmodifications should be customised to the nor-
mal tissue anatomy of the individual patient, the location of
the primary tumour bed and the contour of the breast. In addi-
tion, in cases where the tumour bed is very close to the heart,
treatment at deep inspiration can be advantageous [53–55].
Further research is warranted to understand the dose–re-
sponse relationship leading to radiation-induced cardiovas-
cular disease. Current research focuses on the one hand on
optimising the radiation therapy techniques to limit the expo-
sure of cardiac structures and lung tissue to radiation, and on
the other hand on examining which cardiac substructures are
most related to the induction of late toxicity and mortality
[52,56–58]. Of importance is also the requirement to conduct
proper follow-up, which is indispensable for evaluation of
long-term treatment effects after radiation therapy and to ad-
vise patients on how to adapt their life style in the case of an
elevated risk of cardiovascular toxicity [59].7. Technical developments
Donovan and colleagues were among the first to confirm on a
clinical level the advantages of optimisation of RT dose distri-
bution. In a randomised prospective trial they investigated
the influence of dose homogeneity on late adverse effects
after BCT to evaluate whether the additional costs in infra-
structure and staffing are justified [14]. With forward-planned
IMRT, they minimised dose inhomogeneity in the breast
significantly. Of great importance is that they were able to
associate this with the change in breast appearance during
follow-up as scored by photographic as well as by clinical
assessment. These results confirm the sensitivity of late
normal tissue effects to fraction size [60]. Therefore, 3D dose
planning should be routinely implemented, even more with
hypofractionated RT schedules.
A broad spectrum of RT techniques are described in the lit-
erature, ranging from low complexity (conventional, wedge-based approaches using limited beam angles) to highly mod-
ulated, multiple-angle photon techniques [61–63]. As some of
the highly complex techniques might lead to a higher dose to
the organs at risk (heart, lungs, contralateral breast), their
implementation should be carefully considered and coupled
with other technological improvements [64].
A rapidly increasing number of RT departments are using
hypofractionated RT schedules, especially after the publica-
tion of the long-term results of large prospective trials
[65–67]. With this, whole breast RT duration can be reduced
from the conventional 5 weeks to 3 weeks. Adding to this
obvious advantage to the patients, a boost dose for BCT is
becoming more selectively applied to only those patients with
a high risk of local recurrence, reducing the treatment by
1–1.5 weeks and decreasing the risk of fibrosis.
The use of electrons and brachytherapy as boostmodalities
is gradually being replaced by 3D-CRT photon beam tech-
niques. Interest in this technique has recently been stimulated
with the introduction of the simultaneous integrated boost
(SIB) technique, in which the dose to the whole breast is com-
bined with a simultaneous boost to the primary tumour bed
[68]. Apart from logistical advantages for the RT department,
it significantly reduces the boost field sizes thanks to both im-
proved conformality and electronic equilibrium [69].
Patients with large pendulous breasts may be treated in
the prone position to minimise skin folds in the breast, such
as the infra-mammary fold. Placing the patient in the prone
position also allows the surgical bed to fall farther away from
the rib cage, increasing the distance between the cardiac
structures and the lumpectomy site.
Breathing-adapted treatment reduces the impact of respi-
ratory motion on the motion of the target volume. Treatment
delivery under deep inspiration also increases the distance
between the breast and the heart for left-sided breast cancer
patients, reducing the RT dose to the heart [53–55,70].8. Challenges
8.1. Target volume delineation
The primary objective of radiation therapy is to eradicate
microscopic residual disease after surgery. The areas at high-
est risk of recurrence after mastectomy are the chest wall and
the undissected lymph-node regions. In the case of BCT, the
entire breast can contain residual or potential multicentric
disease as well. On the basis of the work by Holland et al.,
the highest residual tumour cell density is expected to be
adjacent to the original tumour site [71]. This explains why
at least 80% of the early failures after BCT occur in the same
quadrant as the original primary tumour.
The regions to be treated constitute the clinical target vol-
umes, to which an additional margin needs to be included to
account for internal motion, patient motion, and setup uncer-
tainty, resulting in the planning target volume that will be
used for RT planning. The transition from clinically set-up
1D treatments to fully virtually prepared 4D RT plans is highly
dependant on proper target volume delineation, which is con-
sidered by most radiation oncologists as currently being the
weakest link in the quality chain of breast cancer RT, with a
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be clinically significant both in terms of dosimetric target cov-
erage as well as exposure of the organs at risk [73]. To improve
consistency in target volume delineation, a number of initia-
tives have been undertaken, after which it has been demon-
strated that training as well as the availability of clearly
written guidelines decreases inter- and intra-observer vari-
ability [72]. ESTRO has given a high priority to increasing its
online educational and professional services. Within this re-
source, a multifunctional platform for volume delineation
has been created. This will also be used to facilitate the orga-
nisation of teaching courses and the writing of internationally
accepted guidelines.
8.2. Individualisation
To properly individualise, we should take into account several
factors, including prognosis, risk-to-benefit ratios, patient
expectations and specific anatomy. Therefore we should con-
sider every single patient as a unique combination of per-
sonal, disease and anatomical factors. Based on this we can
discuss proper decision-making in a multidisciplinary setting
and with the patient.
As for RT, treatment planning – based on a complete 3D
dataset – can now be fully individualised to the patients’ anat-
omy and the delineated target volumes, taking into account
the dose to normal structures. In general, a standard set-up
RT technique will fit most patients, and every department
should accrue experience with a standard approach that best
fits their own way of working. However, individualisation of
techniques should be done on the basis of the anatomy of
each single patient. As an example, the entire chest wall
may sometimes be treated with electron-beam fields [57].
With a five-field technique a homogeneous dose to the tho-
racic wall (and the IMC if indicated) can be delivered with a
much lower dose to the underlying lungs and heart compared
with tangential photon fields, especially in patients with a
markedly curved thoracic wall [74]. Also, a partially wide tan-
gential approach, including the IMC lymph-node region to-
gether with the chest wall or breast in a single pair of fields,
can be used when a separate IMC field cannot be employed
due to the patients’ anatomy.
8. Future perspectives
The future lies in a multidisciplined approach and a coming
together of the indications for all types of treatment, includ-
ing surgery, RT and systemic treatment. At present, few treat-
ments are clinically linked (such as lumpectomy combined
with whole breast RT). However, we can no longer neglect
the interactions within the therapeutic spectrum. Therefore,
we should focus more on treatment packages instead of sim-
ply adding one treatment to another.
As an example, the management of the axilla is expected
to change markedly in the coming years. Even the standard
use of the sentinel node procedure is challenged in some pa-
tient categories where the need (or lack of need) for systemic
treatment can be estimated on the basis of other prognostic
information. Use of axillary clearance as a routine procedure
is rapidly decreasing andmight even become extinct when re-sults from trials such as the EORTC AMAROS trail become
known [75].
Another example is the issue of the patient at very low risk
who might be offered years of hormonal treatment or a short
course of whole or partial breast RT, with the challenge of
demonstrating the added value of combining both ap-
proaches together. This fits well into the drive to optimise
the cost/benefit ratio of cancer treatment, especially in times
of limited financial resources [76].
The response to systemic treatment can be used in high-
risk patients as a predictor for improved survival. It is likely
that these high-risk patients might benefit most in terms of
overall survival from optimal locoregional treatment [77]. Per-
haps a proportion of these patients might even be treated
without surgery.
Another issue that will only be solved after the presenta-
tion of data from recent prospective trials is the selection of
the areas to be treated. While irradiation of the IMC lymph-
node area is the most strongly debated, an early analysis
did not show an increased level of toxicity [78].
New biological targeted agents should be tested in combi-
nation with RT. Similar to chemotherapy, several studies test-
ing the prognostic and predictive value of genomic and
proteomic tests are being conducted.
The duration of RT for breast cancer has reduced from 6–
7 weeks to 3–4 weeks over the last few years. Further reduc-
tion to even fewer fractions in a shorter time period is the
subject of recent and ongoing trials [79]. This should help to
end the discussion about the sequence of RT and systemic
treatments by decreasing the possible postponement of the
latter with a shorter RT course.Conflict of interest statement
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